Safety and efficacy of daratumumab in combination with bortezomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma

Overview of attention for article published in International Journal of Hematology, December 2017

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Above-average Attention Score compared to outputs of the same age and source (53rd percentile)

Mentioned by

twitter: 5 X users

Citations

dimensions_citation: 10 Dimensions

Readers on

mendeley: 52 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 5 X posts from 5 X users, with an upper bound of 17,116 followers.

RT @Myeloma_Doc: Small Japanese study of #Darzalex with #Velcade/dex finds 100% response rate in relapsed/refractory #myeloma with good tol…

Reply Repost Favourite

RT @Myeloma_Doc: Small Japanese study of #Darzalex with #Velcade/dex finds 100% response rate in relapsed/refractory #myeloma with good tol…

Reply Repost Favourite

RT @Myeloma_Doc: Small Japanese study of #Darzalex with #Velcade/dex finds 100% response rate in relapsed/refractory #myeloma with good tol…

Reply Repost Favourite

RT @Myeloma_Doc: Small Japanese study of #Darzalex with #Velcade/dex finds 100% response rate in relapsed/refractory #myeloma with good tol…

Reply Repost Favourite

Small Japanese study of #Darzalex with #Velcade/dex finds 100% response rate in relapsed/refractory #myeloma with good tolerability: https://t.co/38iBJ1FbnH. https://t.co/jf7gsJwC7L

Reply Repost Favourite